Findings from this study are of great significance which highlight the potential therapeutic strategy by targeting the local Talin-1/Smurf1/Stat3 axis to mitigate β-cell mass loss and enhance insulin secretion in patients with diabetes or hyperglycemia, offering potential avenues for intervention in these conditions. Here, SMURF1 is linked to Hyperglycemia.